Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
US11150238B2 · kind B2 · utility
0Cited by
31References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2018 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Jan 5, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A blood-based sample from a cancer patient is subject to mass spectrometry and the resulting mass spectral data is classified with the aid of a computer to see if the patient is a member of a class of patients having a poor prognosis. If so, the mass spectral data is further classified with the aid of the computer by a second classifier which identifies whether the patient is nevertheless likely to obtain durable benefit from immunotherapy drugs, e.g., immune checkpoint inhibitors, anti-CTLA4 drugs, and high dose interleukin-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.